Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas

23 Jan 2019

Abstract excerpt

PARP inhibitors (PARPis) have remarkable antitumor activity in BRCA mutant ovarian carcinoma. Emerging evidence has shown that responses to PARPis are not limited to BRCA mutant tumors, but could expand to other homologous recombination deficiency (HRD) carcinomas. However, relatively little is known about the efficacy of PARPis in patients with HRD when compared to non-HRD carriers. In this systematic review, 13...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30666631
DOI: 10.1002/ijc.32143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomasPMID 30666631Read ↗

Perspectives on PARP Inhibitor Combinations for Ovarian CancerSemantic proximity Read ↗

Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.Semantic proximity Read ↗

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Therapeutic applications of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancerSemantic proximity Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinicSemantic proximity Read ↗

Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor ResistanceSemantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.